1300031-65-5

Basic information

• Product Name: 4-(4-chloro-6-Methoxy-3-nitroquinolin-7-yl)-3,5-diMethylisoxazole
• Synonyms: 4-(4-chloro-6-Methoxy-3-nitroquinolin-7-yl)-3,5-diMethylisoxazole;4-(4-chloro-6-methoxy-3-nitro-7-quinolyl)-3,5-dimethyl-isoxazole
• CAS NO: 1300031-65-5
• Molecular Formula: C₁₅H₁₂ClN₃O₄
• Molecular Weight: 333.72648
• EINECS: -0
• Mol File: 1300031-65-5.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-(4-chloro-6-Methoxy-3-nitroquinolin-7-yl)-3,5-diMethylisoxazole(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-chloro-6-Methoxy-3-nitroquinolin-7-yl)-3,5-diMethylisoxazole(1300031-65-5)
• EPA Substance Registry System: 4-(4-chloro-6-Methoxy-3-nitroquinolin-7-yl)-3,5-diMethylisoxazole(1300031-65-5)

Safety Data

• Hazardous Substances Data: 1300031-65-5(Hazardous Substances Data)

Usage

Description

4-(4-chloro-6-Methoxy-3-nitroquinolin-7-yl)-3,5-diMethylisoxazole is a complex chemical compound characterized by a quinolinyl group with chlorine and methoxy substitutions, a nitro group, and a diMethylisoxazole group. Its unique molecular structure and potential biological activity suggest it may hold promise for pharmaceutical research and development, although further studies are required to elucidate its properties and applications.

Uses

Used in Pharmaceutical Research and Development:
4-(4-chloro-6-Methoxy-3-nitroquinolin-7-yl)-3,5-diMethylisoxazole is used as a potential candidate in pharmaceutical research and development for its unique molecular structure and potential biological activity. Its specific applications may include targeting various diseases or conditions, depending on the outcomes of further research and development.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 4-(4-chloro-6-Methoxy-3-nitroquinolin-7-yl)-3,5-diMethylisoxazole is used as a compound of interest for the design and synthesis of new drugs. Its structural features may contribute to the development of novel therapeutic agents with improved efficacy and selectivity.
Used in Drug Discovery:
4-(4-chloro-6-Methoxy-3-nitroquinolin-7-yl)-3,5-diMethylisoxazole is utilized in drug discovery processes to identify potential lead compounds. Its unique chemical properties may offer new avenues for the treatment of various diseases, pending further investigation into its pharmacological profile.
Used in Biochemical Studies:
In biochemical research, 4-(4-chloro-6-Methoxy-3-nitroquinolin-7-yl)-3,5-diMethylisoxazole is employed as a tool to study biological processes and mechanisms. Its interaction with biological targets can provide insights into the molecular basis of diseases and the development of therapeutic interventions.

Upstream product

• 1220886-29-2 methyl 4-bromo-5-fluoro-2-nitrobenzoate 
• 1020717-99-0 4-bromo-5-fluoro-2-nitrobenzoic acid 
• 153556-42-4 4-bromo-3-fluorobenzoic acid 
• 1623120-79-5 2-amino-4-bromo-5-methoxybenzoic acid 
• 1256955-36-8 methyl 2-amino-4-bromo-5-methoxybenzoate 
• 1300031-58-6 7-(3,5-dimethyl-4-isoxazolyl)-4-hydroxy-6-(methyloxy)-3-quinolinecarboxylic acid 
• 1300031-59-7 ethyl 7-(3,5-dimethyl-4-isoxazolyl)-4-hydroxy-6-(methyloxy)-3-quinolinecarboxylate 
• 1300031-60-0 1,3-diethyl 2-([[3-(3,5-dimethyl-1,2-oxazol-4-yl)-4-methoxyphenyl]amino]methylidene)propanedioate 
• 1300031-61-1 [3-(3,5-dimethyl-4-isoxazolyl)-4-(methyloxy)phenyl]amine 
• 1300031-62-2 3,5-dimethyl-4-[2-(methyloxy)-5-nitrophenyl]isoxazole 
• 5399-03-1 2-iodo-1-methoxy-4-nitrobenzene 
• 16114-47-9 3,5-dimethylisoxazole-4-boronic acid 
• 1300031-66-6 7-(3,5-dimethyl-4-isoxazolyl)-6-(methyloxy)-3-nitro-4-quinolinol 
• 1300031-67-7 7-(3,5-dimethylisoxazol-4-yl)-6-methoxyquinolin-4-ol 

Downstream Products

• 1300031-64-4 7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-3-nitro-N-((R)-1-phenylethyl)quinolin-4-amine 
• 1300031-50-8 7-(3,5-dimethyl-4-isoxazolyl)-8-(methoxy)-1-[(1R)-1-phenylethyl]-2-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-c]quinoline 
• 1300735-35-6 7-(3,5-dimethyl-4-isoxazolyl)-8-(methoxy)-1-[(1R)-1-phenylethyl]-1H-[1,2,3]triazolo[4,5-c]quinoline 
• 1300031-63-3 7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-N⁴-((R)-1-phenylethyl)quinoline-3,4-diamine 
• 1300736-25-7 7-(3,5-dimethylisoxazol-4-yl)-8-methoxy-1-((R)-1-phenylethyl)-1H-imidazo[4,5-c]quinoline-2(3H)-thione 

Relevant articles and documents

METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE

The present disclosure relates to compounds and methods for modulating the expression of dmpk, and treating diseases and conditions in which dmpk plays an active role. The compound can be a transcription modulator molecule having a first terminus, a second terminus, and oligomeric backbone, wherein: a) the first terminus comprises a DNA-binding moiety capable of noncovalently binding to a nucleotide repeat sequence CAG or CTG; b) the second terminus comprises a protein-binding moiety binding to a regulatory molecule that modulates an expression of a gene comprising the nucleotide repeat sequence CAG or CTG; and c) the oligomeric backbone comprising a linker between the first terminus and the second terminus.

Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative Phenotype

The bromodomain and extraterminal domain (BET) family of epigenetic regulators comprises four proteins (BRD2, BRD3, BRD4, BRDT), each containing tandem bromodomains. To date, small molecule inhibitors of these proteins typically bind all eight bromodomains of the family with similar affinity, resulting in a diverse range of biological effects. To enable further understanding of the broad phenotype characteristic of pan-BET inhibition, the development of inhibitors selective for individual, or sets of, bromodomains within the family is required. In this regard, we report the discovery of a potent probe molecule possessing up to 150-fold selectivity for the N-terminal bromodomains (BD1s) over the C-terminal bromodomains (BD2s) of the BETs. Guided by structural information, a specific amino acid difference between BD1 and BD2 domains was targeted for selective interaction with chemical functionality appended to the previously developed I-BET151 scaffold. Data presented herein demonstrate that selective inhibition of BD1 domains is sufficient to drive anti-inflammatory and antiproliferative effects.

IMIDAZOQUINOLINE COMPOUNDS AS BROMODOMAIN INHIBITORS

The present invention provides compound of formula (I), or an isotopic form, a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a solvate, a polymorph, a prodrug, N-oxide or S-oxide thereof; and processes for their preparation. The invention further relates to pharmaceutical compositions containing said compounds and their use in the treatment of diseases or disorders mediated by bromodomain containing proteins, particularly cancer.